Product Categories
| Country: | United States |
|---|---|
| Tel: | 552-7181 |
| E-mail: | sales@aladdinsci.com |
| QQ: | |
| Skype: | Chat Now! |
| Address: | 14078 Meridian Parkway, Riverside |
|
Aladdin Scientific Corporation is a listed company on the A-share Science and Technology Board (stock code: 688179), which has been deeply engaging in the field of scientific research reagents for more than ten years, and is a manufacturer of scientific research reagents integrating research and development, production and sales. After years of exploration, accumulation and development, it owns six major product lines of chemistry and biochemistry reagents, material sciences, drug-targeting ligands, proteins, antibodies, and I-Quip?? labware. Product line.
Relying on its own e-commerce platform (www.aladdinsci.com), Aladdin provides a huge product line covering hundreds of thousands of scientific research reagents and thousands of consumables/instruments, which are widely used in colleges and universities, scientific research institutes, medical treatment, medicine, pharmaceuticals, diagnostics, new materials, new energy, energy conservation and environmental protection, aerospace and other high-tech industries as well as their upstream and downstream enterprises. Corporation
|
|
| Product Name | MF | CAS | Details |
|---|
| Pascolizumab (anti-IL-4) | 331243-22-2 | Details |
| Lemzoparlimab (anti-CD47) | 2377483-71-9 | Details |
| Otilimab (anti-GM-CSF) | 1638332-55-4 | Details |
| Gantenerumab (anti-Amyloid Beta) | 1043556-46-2 | Details |
| Rilotumumab (anti-HGF) | 872514-65-3 | Details |
| Gevokizumab (anti-IL-1b) | 1129435-60-4 | Details |
| Carotuximab (anti-CD105) | 1268714-50-6 | Details |
| Inebilizumab (anti-CD19) | 1299440-37-1 | Details |
| Zansecimab (anti-ANGPT2) | 2415205-37-5 | Details |
| Imaprelimab (anti-CD146) | 2014343-04-3 | Details |
| Eculizumab (anti-Complement C5) | 219685-50-4 | Details |
| Ontamalimab (anti-MADCAM1) | 2098790-40-8 | Details |
| Tarextumab (anti-NOTCH3) | 1359940-55-8 | Details |
| Bermekimab (anti-IL-1a) | 1401965-15-8 | Details |
| Cusatuzumab (anti-CD70) | 1864871-20-4 | Details |
| Denintuzumab (anti-CD19) | 1630074-14-4 | Details |
| Gemtuzumab (anti-CD33) | 220578-59-6 | Details |
| Enfortumab (anti-NECTIN4) | 1448664-46-7 | Details |
| Teprotumumab (anti-IGF1R) | 1036734-93-6 | Details |
| Sirukumab (anti-IL-6) | 1194585-53-9 | Details |
| Teplizumab (anti-CD3e) | 876387-05-2 | Details |
| Tinurilimab (anti-CEACAM6) | 2226224-30-0 | Details |
| Eldelumab (anti-CXCL10) | 946414-98-8 | Details |
| Emibetuzumab (anti-MET) | 1365287-97-3 | Details |
| Vantictumab (anti-FZD) | 1345009-45-1 | Details |
| Indusatumab (anti-GUCY2C) | 1497400-26-6 | Details |
| Labetuzumab govitecan (anti-CEACAM5) | 1469876-18-3 | Details |
| Prezalumab (anti-B7-H2) | 1523164-68-2 | Details |
| Mezagitamab (anti-CD38) | 2227490-52-8 | Details |
| Depatuxizumab mafodotin (anti-EGFR) | 1585973-65-4 | Details |
| Avdoralimab (anti-C5AR1) | 2226393-85-5 | Details |
| Polatuzumab (anti-CD79b) | 2279068-37-8 | Details |
| Daclizumab (anti-IL2RA) | 152923-56-3 | Details |
| Seribantumab (anti-ERBB3) | 1334296-12-6 | Details |
| Abelacimab(anti-Factor XI) | 2098724-83-3 | Details |
| Enoblituzumab (anti-CD276) | 1353485-38-7 | Details |
| Dinutuximab (anti-GD2) | 1363687-32-4 | Details |
| Fulranumab (anti-NGF) | 902141-80-4 | Details |
| Lorvotuzumab (anti-CD56) | 339306-30-8 | Details |
| Dostarlimab (anti-PD-1) | 2022215-59-2 | Details |
| Datopotamab (anti-TROP2) | 2267989-53-5 | Details |
| Enokizumab (anti-IL-9) | 909875-08-7 | Details |
| Brazikumab (anti-IL-23) | 1610353-18-8 | Details |
| Belimumab (anti-TNFSF13B) | 356547-88-1 | Details |
| Ulocuplumab (anti-CXCR4) | 1375830-34-4 | Details |
| Ponsegromab (anti-GDF15) | 2368950-15-4 | Details |
| Ocrelizumab (anti-CD20) | C19H16N2O5 | 637334-45-3 | Details |
| Girentuximab (anti-CA9) | 916138-87-9 | Details |
| Efalizumab (anti-ITGAL) | 214745-43-4 | Details |
| Vunakizumab (anti-IL-17a) | 1792181-33-9 | Details |
| Envafolimab (anti-PD-L1) | 2102192-68-5 | Details |
| Talquetamab (anti-GPRC5D) | 2226212-40-2 | Details |
| Figitumumab (anti-IGF1R) | 943453-46-1 | Details |
| Panitumumab (anti-EGFR) | 339177-26-3 | Details |
| Farletuzumab (anti-FOLR1) | 896723-44-7 | Details |
| Muromonab (anti-CD3) | 140608-64-6 | Details |
| Sotigalimab (anti-CD40) | 2305607-45-6 | Details |
| Anifrolumab (anti-IFNAR1) | 1326232-46-5 | Details |
| Brentuximab (anti-TNFRSF8) | 2088770-90-3 | Details |
| Onvatilimab (anti-VISTA) | 1969313-51-6 | Details |
| Patritumab (anti-ERBB3) | 1262787-83-6 | Details |
| Fletikumab (anti-IL-20) | 1357158-22-5 | Details |
| Abituzumab (anti-ITGAV) | 1105038-73-0 | Details |
| Mirvetuximab (anti-FOLR1) | 1453084-36-0 | Details |
| Margetuximab (anti-HER2) | 1350624-75-7 | Details |
| Emicizumab (anti-Factor IX) | 1610943-06-0 | Details |
| Onartuzumab (anti-MET) | 1133766-06-9 | Details |
| Ficlatuzumab (anti-HGF) | 1174900-84-5 | Details |
| Zilovertamab (anti-ROR1) | 2485779-13-1 | Details |
| Mavrilimumab (anti-CD116) | 1085337-57-0 | Details |
| Relatlimab (anti-LAG-3/CD223) | 1673516-98-7 | Details |
| Belantamab (anti-TNFRSF17) | 2061894-48-0 | Details |
| Motavizumab (anti-RSV-F) | 677010-34-3 | Details |
| Varlilumab (anti-TNFRSF7) | 1393344-72-3 | Details |
| Eptinezumab (anti-CGRP) | 1644539-04-7 | Details |
| Ofatumumab (anti-CD20) | 679818-59-8 | Details |
| Ibalizumab (anti-CD4) | 680188-33-4 | Details |
| Omburtamab (anti-CD276) | 1895083-75-6 | Details |
| Erenumab (anti-CALCRL) | 1582205-90-0 | Details |
| Selicrelumab (anti-CD40) | 1622140-49-1 | Details |
| Sifalimumab (anti-IFNa1) | 1006877-41-3 | Details |
| Nadunolimab (anti-IL-1 RAcP) | 2171061-85-9 | Details |
| Canakinumab (Anti-IL-1b) | 914613-48-2 | Details |
| Oleclumab (anti-CD73) | 1803176-05-7 | Details |
| Olokizumab (anti-IL-6) | 1007223-17-7 | Details |
| Mupadolimab (anti-CD73) | 2451856-97-4 | Details |
| Bemarituzumab (anti-FGFR2) | 1952272-74-0 | Details |
| Aducanumab (anti-APP) | 1384260-65-4 | Details |
| Etokimab (anti-IL-33) | 2022981-44-6 | Details |
| Rovalpituzumab (anti-DLL3) | 1613313-01-1 | Details |
| Otelixizumab (anti-CD3) | 881191-44-2 | Details |
| Aprutumab (anti-FGFR2) | 1634620-63-5 | Details |
| Amatuximab (anti-MSLN) | 931402-35-6 | Details |
| Naxitamab (anti-GD2) | 1879925-92-4 | Details |
| Etrolizumab (anti-α4β7) | 1044758-60-2 | Details |
| Fezakinumab (anti-IL-22) | 1007106-86-6 | Details |
| Penpulimab (anti-PDCD1) | 2350298-92-7 | Details |
| Mepolizumab (anti-IL-5) | 196078-29-2 | Details |
| Simtuzumab (anti-LOXL2) | 1318075-13-6 | Details |
| Sofituzumab (anti-MUC16) | 1615692-28-8 | Details |
| Product Total： Product Page： | ||||
| 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 | ||||